Past papers have shown prognosis-related factors in GBM patients receiving standard radiochemotherapy, such as the extent of removal [2–4], patient age, isocitrate dehydrogenase (IDH) mutations, and methylation status of O6-methylguanine-DNA methyl-transferase (MGMT) promotor among others [5–7]. The gene discussed is IDH1; the disease is glioblastoma.